JP2012516140A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516140A5
JP2012516140A5 JP2011546814A JP2011546814A JP2012516140A5 JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 2012516140 A5 JP2012516140 A5 JP 2012516140A5
Authority
JP
Japan
Prior art keywords
polypeptide
isolated
cell
oligopeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516140A (ja
JP5792630B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/050839 external-priority patent/WO2010086294A2/en
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
US61/147,892 2009-01-28
EP09151495.0 2009-01-28
EP09151495 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 true JP2012516140A5 (https=) 2013-03-14
JP5792630B2 JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (https=)
EP (1) EP2391635B1 (https=)
JP (1) JP5792630B2 (https=)
WO (1) WO2010086294A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
CA2995103A1 (en) 2015-08-07 2017-02-16 University Of Virginia Patent Foundation Identification of class i mhc associated glycopeptides as targets for cancer immunotherapy
CN109748952B (zh) 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
WO2019241483A1 (en) * 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants
WO2025231560A1 (en) * 2024-05-08 2025-11-13 The Governing Council Of The University Of Toronto Vaccine to mobilize b cells for therapy

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP0534615B1 (en) 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
WO1995003777A1 (en) 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
ATE320444T1 (de) 1991-08-26 2006-04-15 Scripps Research Inst Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
JP3657603B2 (ja) 1993-02-26 2005-06-08 ザ スクリップス リサーチ インスティテュート Ｂ型肝炎のウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
AU6103896A (en) 1995-06-07 1996-12-30 Cytel Corporation Manufacture and purification of peptides
PT876398E (pt) 1996-01-24 2002-12-31 Epimmune Inc Inducao de respostas imunitarias contra determinantes desejados
CN1225590A (zh) * 1996-03-11 1999-08-11 埃皮曼尼公司 对hla分子结合亲和力提高的肽
WO1997034621A1 (en) 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
CA2278189A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
EP1017810B1 (en) 1997-10-10 2004-05-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agonist and antagonist peptides of carcinoembryonic antigen (cea)
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1080370A4 (en) * 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
DE69940774D1 (de) 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
WO2000044775A2 (en) 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
WO2001021189A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001024810A1 (en) 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1239866A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
EP1235848A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
CA2393662A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
JP2003517310A (ja) 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
JP2003521245A (ja) 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
WO2002020035A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
CA2420225A1 (en) 2000-09-01 2002-03-14 Pharmexa Inc. Hla-a2.1 binding peptides and their uses
CA2421448A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
BR0017332A (pt) 2000-09-08 2003-10-07 Epimmune Inc Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
EP1495322A4 (en) 2002-04-05 2006-09-06 Epimmune Inc HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
CA2500955A1 (en) 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
WO2004053086A2 (en) 2002-12-06 2004-06-24 Epimmune, Inc. Plasmodium falciparum antigens and methods of use
WO2004052917A2 (en) 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
PT1620456E (pt) 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CA2566506A1 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
CN1993141A (zh) 2004-06-04 2007-07-04 法麦克萨有限公司 诱导针对肺炎链球菌多糖的免疫应答
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
AU2007300663A1 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Similar Documents

Publication Publication Date Title
JP2012516140A5 (https=)
Babin et al. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
JP2021001216A (ja) インフルエンザ抗原送達用のベクターおよび構築体
JP2013517783A5 (https=)
JP2014500724A5 (https=)
JP2014503172A5 (https=)
JP2015521467A5 (https=)
JP2012501959A5 (https=)
JP2009540801A5 (https=)
JP2011516070A5 (https=)
JP2015501656A5 (https=)
JP2019506175A5 (https=)
JP2015212284A5 (https=)
JP2015509707A5 (https=)
JP2012515557A5 (https=)
JP2013520487A5 (https=)
JP2010532656A5 (https=)
HRP20130022T1 (hr) Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora
JP2014504297A5 (https=)
JP2020502075A5 (https=)
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
JP2010535504A5 (https=)
CN103864905B (zh) 一种o型口蹄疫ctl表位肽及筛选方法
CN102178950B (zh) 一种亚单位疫苗免疫佐剂及应用
TW200716166A (en) Lawsonia intracellularis immunological proteins